Nathan Pennell Appointed Senior Vice President and Worldwide Head of Hematology Oncology Medical Affairs at Bristol Myers Squibb

Nathan Pennell, MD, PhD, has announced his new role as Senior Vice President and Worldwide Head of Hematology Oncology Medical Affairs at Bristol Myers Squibb (BMS). He shared the news with his professional network on LinkedIn, stating:

“I’m happy to share that I’m starting a new position as SVP, Worldwide Head of Hematology Oncology Medical Affairs at Bristol-Myers Squibb!”

A Distinguished Career in Oncology

Dr. Pennell is widely recognized as a leader in the field of thoracic oncology, with a career dedicated to advancing cancer care through research, clinical leadership, and medical education. Before joining BMS, he held prominent roles at the Cleveland Clinic Taussig Cancer Institute, where he served as Director of the Lung Cancer Medical Oncology Program. His work has helped shape treatment strategies for lung cancer and other thoracic malignancies, earning him recognition as both a clinician and educator.

Joining Bristol Myers Squibb’s Global Mission

Bristol Myers Squibb is one of the world’s leading biopharmaceutical companies, widely recognized for its dedication to advancing cancer research and treatment. The company has built a strong global reputation in hematology and immuno-oncology, with a pipeline and portfolio that include groundbreaking therapies for some of the most challenging cancers. By strengthening its leadership team in hematology and oncology medical affairs, BMS underscores its ongoing mission to discover, develop, and deliver innovative medicines that transform patients’ lives.

The company has invested heavily in advancing immunotherapy, cell therapy, and precision medicine, shaping new standards of care for patients across the globe. Its research and development centers collaborate with top academic institutions, biotech innovators, and healthcare providers to ensure that promising discoveries translate into tangible therapies. With a portfolio that includes pioneering treatments for multiple myeloma, lymphoma, and other hematologic malignancies, BMS continues to play a pivotal role in transforming patient outcomes. The integration of leaders like Dr. Pennell into this mission underscores the company’s focus on both scientific excellence and patient-centered care.

More posts featuring Bristol Myers Squibb on Oncodaily can be found here.

A Warm Welcome from Bristol Myers Squibb Leadership

The announcement of Dr. Pennell’s appointment has already generated enthusiasm among colleagues at Bristol Myers Squibb. Dr. Tania Small, Senior Vice President and Head of Medical Affairs, shared on LinkedIn:

“Thrilled to welcome Dr. Nate Pennell to Bristol Myers Squibb as our new Senior Vice President, Worldwide Head of Medical Affairs, Hematology & Oncology.

Nate is a world-class oncologist, a tireless advocate, and a true innovator in lung cancer research and care. His work has transformed standards and brought hope to countless patients and families.

He will now head our Hematology & Oncology Medical Affairs organization with the same patient-first mindset, scientific rigor, and bold vision that have defined his career.

I’m excited to partner with Nate as we push the boundaries of science, strengthen BMS’ partnerships across the healthcare community, and – most importantly – transform patients’ lives!”

In response, Dr. Pennell reposted with gratitude and reflection on his career journey:

“After more than two decades in oncology as a clinician, researcher and leader at the Cleveland Clinic, I’m stepping into a new chapter and joining Bristol Myers Squibb as Senior Vice President, Worldwide Head of Medical Affairs, Hematology & Oncology.

This transition is more than a career move. It’s about expanding my ability to make a difference for patients-bringing science from the bench and bedside to the global level. At BMS, I’ll have the privilege to work with brilliant colleagues around the world who are driven by the same purpose that’s guided me throughout my career: delivering better outcomes and more hope to people living with cancer.

I’m deeply grateful for the warm welcome and can’t wait to get started. Here’s to advancing science, transforming care, and making a real-world impact – together.”

Looking Ahead

Dr. Pennell’s transition to this new role marks an exciting chapter not only in his career but also in the broader oncology community. His leadership is expected to foster stronger connections between research, clinical practice, and patient outcomes at a global scale.

More posts featuring Dr. Nathan Pennell on Oncodaily.

Written by Sergey Badalyan, MD.